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ABSTRACT
Background. The prospective Neoadjuvant Breast Sym-
phony Trial (NBRST) study found that MammaPrint/
BluePrint functional molecular subtype is superior to
conventional immunohistochemistry/fluorescence in situ
hybridization subtyping for predicting pathologic complete
response (pCR) to neoadjuvant chemotherapy. The purpose
of this substudy was to determine if the rate of pCR is
affected by tumor size.
Methods. The NBRST study includes breast cancer
patients who received neoadjuvant chemotherapy. Mam-
maPrint/BluePrint subtyping classified patients into four
molecular subgroups: Luminal A, Luminal B, HER2 (hu-
man epidermal growth factor receptor 2), and Basal type.
Probability of pCR (ypT0/isN0) as a function of tumor size
and molecular subgroup was evaluated.
Results. A total of 608 patients were evaluable with
overall pCR rates of 28.5 %. Luminal A and B patients had
significantly lower rates of pCR (6.1 and 8.7 %, respec-
tively) than either basal (37.1 %) or HER2 (55.0 %)
patients (p\ 0.001). The probability of pCR significantly
decreased with tumor size [5 cm [p = 0.022, odds ratio
(OR) 0.58, 95 % confidence interval (CI) 0.36, 0.93]. This
relationship was statistically significant in the Basal
(p = 0.026, OR 0.46, 95 % CI 0.23, 0.91) and HER2
(p = 0.039, OR 0.36, 95 % CI 0.14, 0.95) subgroups. In
multivariate logistic regression analyses, the dichotomized
tumor size variable was not significant in any of the
molecular subgroups.
Discussion. Even though tumor size would intuitively be a
clinical determinant of pCR, the current analysis showed
that the adjusted OR for tumor size was not statistically
significant in any of the molecular subgroups. Factors
significantly associated with pCR were PR status, grade,
lymph node status, and BluePrint molecular subtyping,
which had the strongest correlation.
Neoadjuvant chemotherapy (NCT) was initially shown
to downsize many large or locally advanced breast cancers,
thus increasing the likelihood of clear margins with a
mastectomy or lumpectomy. For triple-negative and HER2
(human epidermal growth factor receptor 2) tumors,
pathologic complete response (pCR) correlates with
improved survival.1–5
The Neoadjuvant BReast Symphony Trial (NBRST)
found that MammaPrint/BluePrint molecular subtyping
reclassifies 22 % (94 of 426) of tumors. MammaPrint/
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BluePrint molecular subtyping reassigned patients with
more responsive disease to the HER2 and Basal categories
while reassigning patients with less responsive disease to
the Luminal categories. These findings suggest that com-
pared to immunohistochemistry (IHC)/fluorescence in situ
hybridization (FISH), MammaPrint/BluePrint more accu-
rately identifies patients with disease likely to respond or
not respond to NCT.6
NCT is increasingly being adopted in the clinical man-
agement of patients with more locally advanced disease
and/or more aggressive tumor types. Several identified
reasons for this trend include the following: an opportunity
to observe tumor response to chemotherapy; improvement
in operability; and association of improved survival for
more aggressive subtypes in patients who experience
pCR.1–5 In light of improvements in NCT regimens, there
has been an increased use of this approach in patients with
smaller tumors, who in the past would have more com-
monly gone straight to surgical lumpectomy. This has
generally been seen in patients with either triple-negative
or HER2 tumors with the hope that it would lead to a pCR
and presumably better long-term survival.
Intuitively, it seems that patients with smaller tumors
would more often experience a pCR than those with larger
tumors, which would in turn lead to an additional survival
benefit. Thus, the purpose of this unplanned substudy was
to determine if the pCR rate is also affected by tumor size
and if the tumor size effect is modified by molecular sub-
type as determined by BluePrint molecular subtyping.
PATIENTS AND METHODS
Patients
Patients with histologically proven breast cancer, who
had started or were scheduled to start NCT therapy or
neoadjuvant hormone therapy, after successful Mam-
maPrint/BluePrint assay were enrolled onto the prospective
NBRST registry trial between June 2011 and November
2014 from 62 U.S. institutions. The trial was approved by
institutional review boards in all participating centers and
registered with ClinicalTrials.gov (NCT01479101). Before
registration, all patients provided signed informed consent
for the trial and for research on their tumor samples.
Excluded from the study were patients who had an exci-
sional biopsy or axillary dissection; patients with
confirmed distant metastatic disease; patients with any
prior chemotherapy, radiotherapy, or endocrine therapy for
the treatment of breast cancer; and any serious uncontrolled
intercurrent infections or other serious uncontrolled
comorbid disease. Treatment was at the discretion of the
physician adhering to either National Comprehensive
Cancer Network—approved or other peer-reviewed,
established regimens. No specific recommendations were
given for the selection to treat patients with neoadjuvant
treatment. The NBRST registry is a unique, large, real-
world database of U.S. patients treated in high-volume
breast programs that provides insight into physician choi-
ces for this neoadjuvant treatment—eligible population.
For the current substudy, patients treated with neoadjuvant
endocrine therapy were excluded; only patients with
invasive ductal carcinoma were included.
Molecular and Clinical Characteristics
The 70-gene expression profile MammaPrint and the 80-
gene molecular subtyping profile BluePrint were assessed
from the fresh or formalin-fixed, paraffin-embedded core
needle biopsy at the centralized Agendia Laboratory blin-
ded for clinical and pathologic data. Microarray analysis
(RNA labeling, microarray hybridization, and scanning)
was performed on the RNA, which was cohybridized with
a standard reference to the custom-designed diagnostic
chip, each containing oligonucleotide probes for the pro-
files in triplicate or more.7,8
Four distinct molecular subgroups—Luminal A, Luminal
B, HER2, and Basal—were identified and used for further
analysis. In this study, we defined Luminal A-type tumors as
Luminal type by BluePrint with a Low Risk score by
MammaPrint, and Luminal B-type tumors as BluePrint
Luminal type with a MammaPrint High Risk score.
Hormone receptor status [estrogen receptor (ER) and
progesterone receptor (PR) status] and HER2 status were
determined locally on pretreatment core biopsy samples.
Both ER and PR status were determined by IHC and were
considered positive if there was C1 % positive staining.
HER2 status was determined by IHC and/or FISH assays
locally. HER2 status was regarded as positive if there was
3? staining and/or FISH positivity according to American
Society of Clinical Oncology/College of American Pathol-
ogists HER2 testing guidelines at the time of diagnosis.
Objectives and Endpoints
The primary study endpoint was pCR, defined as the
absence of invasive carcinoma in both the breast and axilla
at microscopic examination of the resection specimen,
regardless of the presence of carcinoma-in situ (ypT0/
isN0). All patients underwent pretreatment imaging of their
primary tumor performed. The largest pre-NCT tumor size
measurement from diagnostically used mammography,
ultrasound, magnetic resonance imaging, positron emission
tomography combined with computed tomography, posi-
tron emission mammography, or computed tomography
was used. T stage was determined by the treating physician
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according to the American Joint Committee on Cancer
(AJCC) 7th edition breast cancer staging.6
To determine whether lymph node status was relevant in
the current analysis, we also analyzed the data using a
definition of pCR in which lymph node status was not
included (ypTis/0).
Statistical Analysis
Rates of pCR were calculated for each MammaPrint/
BluePrint molecular subtype, tumor size subgroup, and
tumor size by molecular subtype; the pCR rates are pre-
sented as proportions of the indicated subgroup.
Logistic regression was used to model the probability of
pCR as a function of tumor size. This was modeled for the
entire cohort. The odds ratio (OR) estimated from the
logistic regression analysis was associated with a 2.1 cm
change in tumor size (approximately equal to 1 standard
deviation). In an effort to make an easily interpretable and
useful tool for clinicians, we sought to establish a
dichotomous variable for tumor size in order to evaluate
differential pCR rates with respect to tumor size in specific
molecular subtypes. Regarding the AJCC staging system,
description of the primary tumor involves both size and
extent of the tumor; the largest tumor diameter of T1 and
T2 staged tumors is necessarily less than or equal to 5 cm.
Logistic regression was therefore used to model the prob-
ability of pCR as a function of a tumor size variable
dichotomized at 5 cm in the entire cohort and in each
molecular subtype separately. Univariate logistic regres-
sion analyses of pCR were evaluated to identify individual
patient and tumor prognostic factors. Significant factors
from the univariate analyses were included in a multi-
variate modeling procedure in the overall cohort. Backward
elimination followed by forward selection was performed
to identify independently prognostic factors. The dichot-
omized tumor size variable was then included in the
multivariate model to estimate an adjusted tumor size ORs
for each of the three BluePrint molecular subtypes.
Fisher’s exact test was used to compare pCR rates by
molecular subgroup and by T stage.
All calculations were performed by SAS 9.3 (SAS
Institute, Cary, NC).
RESULTS
Table 1 lists the pretreatment patient and tumor char-
acteristics for the 608 evaluable patients per MammaPrint/
BluePrint Molecular Subtyping group. The median age of
the patients was 52 years.
Tumor ER and PR status at diagnosis was determined in
tumor samples from 606 patients; 60.1 % were ER positive
and 47.9 % were PR positive. HER2 status at diagnosis
was determined in tumor samples from 605 patients, and
33.2 % were HER2 positive. The median largest diameter
of the primary tumor was 33 mm, ranging from 7 to
122 mm. A total of 25.7 % of patients presented with T3 or
T4 tumors, and 61.0 % of the patients presented with
clinically node-positive disease. Data analysis revealed that
95.8 % had tumors of intermediate or high histologic
grade.
Review of the chemotherapy regimens showed that the
most commonly used regimens in clinical HER2-negative
patients were: 59 % AC (doxorubicin/cyclophosphamide)
followed by a taxane, 15 % TC (docetaxel/cyclophos-
phamide), and 11 % TAC (docetaxel/doxorubicin/cyclop
hosphamide). Of the HER2-enriched patients, 96 % received
trastuzumab simultaneously with NCT, and 26 % of these
patients received trastuzumab and pertuzumab. Before U.S.
Food and Drug Administration approval of pertuzumab in
the neoadjuvant setting (September 2013), 57 % received
TCH (docetaxel/carboplatin/trastuzumab), and 28 %
received AC followed by TH (doxorubicin/cyclophos-
phamide followed by docetaxel/trastuzumab). After
September 2013, the following regimen were mostly used:
50 % TCHP (docetaxel/carboplatin/trastuzumab/per-
tuzumab), 20 % TCH (docetaxel/carboplatin/trastuzumab),
and 10 % THP (docetaxel/trastuzumab/pertuzumab).
A total of 89 % of patients completed their planned
NCT without any modifications. Eight percent had dose
modifications because of toxicities, 2 % stopped NCT early
because of tumor progression, and no reason was specified
for the remaining 1 %.
The overall pCR (ypT0/isN0) rate was 28.5 %. Com-
parison of pCR rates across the four MammaPrint/
BluePrint molecular subgroups (on 3 degrees of freedom)
was highly significant (p\ 0.001). Luminal A tumors had
6.1 % pCR rate, which was not statistically significantly
different (p = 0.604) from the pCR rate of 8.7 % in
Luminal B tumors. The pCR rates for Luminal A and B
subtypes were statistically significantly less than the pCR
rates for Basal (p\ 0.001 and p\ 0.001, respectively) and
HER2 subtypes (p\ 0.001 and p\ 0.001, respectively).
The pCR rates for Basal (37.1 %) and HER2 (55.0 %)
tumors also differed significantly (p = 0.002).
The rates for experiencing pCR by clinical T stage were
as follows: T1 28.2 % (22 of 78), T2 31.8 % (119 of 374),
T3 18.8 % (25 of 133), and T4 30.4 % (7 of 23) (Fisher’s
exact test, p = 0.035). Moreover, the pCR rate for T1 and
T2 stage tumors combined (31.2 %) was statistically sig-
nificantly higher (p = 0.006) than the observed pCR rate in
T3 stage tumors (18.8 %). Figure 1 shows the pCR rate
according by clinical T stage and molecular subtype (ex-
cluding T4).
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TABLE 1 Baseline patient characteristics by MammaPrint/BluePrint molecular subtyping group
Characteristic All patients (n = 608) Patients by subtype
Luminal A (n = 66) Luminal B (n = 183) HER2 (n = 111) Basal (n = 248)
Median age (range) 52 (18–89) 51 (33–69) 54 (22–79) 49 (23–81) 52 (18–89)
Clinical tumor size (mm)
Median (range) 33 (7–122) 32 (7–110) 35 (10–120) 31 (9–100) 31 (7–122)
Tumor stage
cT1 78 (13 %) 4 (6 %) 22 (12 %) 14 (13 %) 38 (15 %)
cT2 374 (62 %) 42 (64 %) 116 (63 %) 65 (59 %) 151 (61 %)
cT3 133 (22 %) 17 (26 %) 37 (20 %) 26 (23 %) 53 (21 %)
cT4 23 (4 %) 3 (5 %) 8 (4 %) 6 (5 %) 6 (2 %)
Nodal stage
cN0 228 (38 %) 27 (41 %) 48 (26 %) 38 (34 %) 115 (46 %)
cN1 308 (51 %) 33 (50 %) 109 (60 %) 62 (56 %) 104 (42 %)
cN2 31 (5 %) 2 (3 %) 12 (7 %) 4 (4 %) 13 (5 %)
cN3 18 (3 %) 2 (3 %) 3 (2 %) 2 (2 %) 11 (4 %)
Missing 23 (4 %) 2 (3 %) 11 (6 %) 5 (5 %) 5 (2 %)
Tumor grade
1 25 (4 %) 12 (18 %) 10 (5 %) 2 (2 %) 1 (\ 1 %)
2 188 (31 %) 41 (62 %) 73 (40 %) 40 (36 %) 34 (14 %)
3 384 (63 %) 12 (18 %) 94 (51 %) 66 (59 %) 212 (85 %)
Missing 11 (2 %) 1 (2 %) 6 (3 %) 3 (3 %) 1 (\ 1 %)
ER status (IHC)
Negative 242 (40 %) 1 (2 %) 2 (1 %) 55 (50 %) 184 (74 %)
Positive 364 (60 %) 65 (98 %) 181 (99 %) 56 (50 %) 62 (25 %)
Missing 2 (\1 %) 0 0 0 2 (1 %)
PR status (IHC)
Negative 316 (52 %) 0 25 (14 %) 75 (68 %) 216 (87 %)
Positive 290 (48 %) 66 (100 %) 158 (86 %) 36 (32 %) 30 (12 %)
Missing 2 (\1 %) 0 0 0 2 (1 %)
HER2 status (IHC/FISH)
Negative 404 (66 %) 54 (82 %) 132 (72 %) 1 (1 %) 217 (88 %)
Positive 201 (33 %) 12 (18 %) 51 (28 %) 110 (99 %) 28 (11 %)
Missing 3 (\ 1 %) 0 0 0 3 (1 %)
MammaPrint
Low Risk 68 (11 %) 66 (100 %) 0 2 (2 %) 0
High Risk 540 (89 %) 0 183 (100 %) 109 (98 %) 248 (100 %)
Neoadjuvant treatment
AC[T 259 (43 %) 39 (59 %) 94 (51 %) 1 (1 %) 125 (50 %)
TC 59 (10 %) 9 (14 %) 24 (13 %) 0 (0 %) 26 (10 %)
TAC 48 (8 %) 4 (6 %) 13 (7 %) 2 (2 %) 27 (11 %)
TCH 95 (16 %) 2 (3 %) 25 (14 %) 53 (48 %) 15 (6 %)
AC[TH 43 (7 %) 5 (8 %) 8 (4 %) 55 (50 %) 8 (3 %)
THCP 34 (6 %) 4 (7 %) 10 (5 %) 17 (15 %) 3 (1 %)
Other 73 (12 %) 6 (9 %) 9 (5 %) 16 (14 %) 44 (18 %)
Surgery
Mastectomy 346 (57 %) 40 (61 %) 102 (56 %) 65 (59 %) 139 (56 %)
Lumpectomy 262 (43 %) 26 (39 %) 81 (44 %) 46 (41 %) 109 (44 %)
Imaging (before NCT)
MRI 287 (47 %) 27 (41 %) 95 (52 %) 51 (46 %) 114 (46 %)
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There were 602 patients with known tumor size included
in the tumor size analyses. Because the pCR rate failed to
be statistically significantly different and was low among
the Luminal A and B subgroups, we decided to pool
Luminal A and B in the analysis of tumor size. Subsequent
analyses of tumor size were across three BluePrint
molecular subgroups: pooled Luminal, HER2, and Basal.
The probability of pCR significantly decreased with
increasing tumor size as a continuous measure (p = 0.027).
The OR of pCR associated with a 2.1 cm difference in
tumor size (approximately 1 standard deviation) was 0.80
[95 % confidence interval (CI) 0.66, 0.98] (Fig. 2;
Table 2). Analysis of the tumor size variable dichotomized
at B5 versus[5 cm indicated the probability of pCR was
significantly decreased in tumors[5 cm relative to smaller
tumors (p = 0.022, OR 0.58, 95 % CI 0.36, 0.93).
With significant difference in overall pCR rate for tumor
size[5 versus B5 cm, we investigated the relationship of
tumor size dichotomized at 5 cm with probability of
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FIG. 1 pCR (ypT0/isN0) rate according by clinical T stage and
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FIG. 2 pCR (ypT0/isN0) rate according to tumor size and BluePrint
subtype
TABLE 1 continued
Characteristic All patients (n = 608) Patients by subtype
Luminal A (n = 66) Luminal B (n = 183) HER2 (n = 111) Basal (n = 248)
Mammogram 151 (25 %) 23 (35 %) 47 (26 %) 32 (29 %) 49 (20 %)
Ultrasound 135 (22 %) 16 (24 %) 33 (18 %) 22 (20 %) 64 (26 %)
PET 18 (3 %) 0 6 (3 %) 2 (2 %) 10 (4 %)
Other 17 (3 %) 0 2 (1 %) 4 (4 %) 11 (4 %)
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2, IHC immunohistochemistry, FISH fluo-
rescence in situ hybridization, A doxorubicin, T taxane, C cyclophosphamide, H trastuzumab, P pertuzumab, THCP docetaxel–carboplatin–
trastuzumab–pertuzumab, NCT neoadjuvant chemotherapy, MRI magnetic resonance imaging, PET positron emission tomography
TABLE 2 pCR (ypT0/isN0) rate by tumor size and MammaPrint/BluePrint molecular subtyping group
Tumor size No. pCR/total (%) No. pCR/total (%) per MammaPrint/BluePrint subtyping group
Luminal A Luminal B HER2 Basal
B2 cm 25/89 (28 %) 0/8 (0 %) 2/22 (9 %) 9/15 (60 %) 14/44 (32 %)
2.1–3 cm 66/188 (35 %) 4/22 (18 %) 3/52 (6 %) 20/38 (53 %) 39/76 (51 %)
3.1–4 cm 34/116 (29 %) 0/14 (0 %) 3/42 (7 %) 10/14 (71 %) 21/46 (46 %)
4.1–5 cm 18/76 (24 %) 0/7 (0 %) 2/25 (8 %) 11/17 (65 %) 5/27 (19 %)
[5.0 cm 27/133 (20 %) 0/15 (0 %) 6/41 (15 %) 8/23 (35 %) 13/54 (24 %)
Total 170/602 (28 %) 4/66 (6 %) 16/182 (9 %) 58/107 (54 %) 92/247 (37 %)
Odds ratio for pCRa (95 % CI) 0.58 (0.36, 0.93) 1.53 (0.56, 4.17) 0.36 (0.14, 0.95) 0.46 (0.23, 0.91)
pCR pathologic complete response, CI confidence interval
a Odds ratio for pCR associated with tumors with size[5 cm relative to B5 cm
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subgroups. When analyzed by BluePrint molecular sub-
group, this relationship was statistically significant in the
Basal subgroup (p = 0.026, OR 0.46, 95 % CI 0.23, 0.91)
and the HER2 subgroup (p = 0.039, OR 0.36, 95 % CI
0.14, 0.95). In comparison, the dichotomized tumor size
variable did not correlate with pCR rate in the pooled
Luminal subgroup (p = 0.411).
The following factors were found to be significantly
(p\ 0.05) associated with the odds of experiencing pCR
based on univariate logistic regression analyses (Table 3):
clinical lymph node status, clinical tumor stage, tumor
grade, ER status, PR status, HER2 status, MammaPrint
result, and BluePrint result. The following factors were
independently associated with the odds of experiencing
pCR based on multivariate logistic regression modeling:
clinical lymph node status, tumor grade, PR status, HER2
status, and BluePrint result. When the dichotomized tumor
size variable was added to the multivariate base model and
assessed within each BluePrint molecular subtype, the
adjusted ORs for tumor size[5 versus B5 cm tumor were
not significant in any of the BluePrint molecular subgroups
(Basal subgroup, OR 0.56, 95 % CI 0.27, 1.17, p = 0.123;
TABLE 3 Univariate analysis of patient and tumor characteristics associated with pCR (ypT0/isN0) versus incomplete pathologic primary









All patients 173 (28 %) 435 (72 %)
Patient age
B50 years 81 (29 %) 199 (71 %) 0.811
[50 years 92 (28 %) 236 (72 %)
IHC ER status at diagnosisa
Positive 65 (18 %) 299 (82 %) \0.001
Negative 107 (44 %) 135 (56 %)
PR status at diagnosisa
Positive 38 (13 %) 252 (87 %) \0.001 0.025 0.51 (0.28, 0.92)
Negative 134 (42 %) 182 (58 %) Ref.
HER2 status at diagnosisa
Positive 84 (42 %) 117 (58 %) \0.001 \0.001 2.70 (1.72, 4.21)
Negative 88 (22 %) 316 (78 %) Ref.
Grade at diagnosisa
1 1 (4 %) 24 (96 %) \0.001 0.025 0.22 (0.03, 1.80)
2 34 (18 %) 154 (82 %) 0.52 (0.30, 0.88)
3 134 (35 %) 250 (65 %) Ref.
T stage
T1 22 (28 %) 56 (72 %) 0.046
T2 119 (32 %) 255 (68 %)
T3 25 (19 %) 108 (81 %)
T4 7 (30 %) 16 (70 %)
Initial lymph node statusa
Negative 90 (39 %) 138 (61 %) \0.001 \0.001 2.08 (1.36, 3.21)
Positive 78 (22 %) 279 (78 %) Ref.
BluePrint-subtype status
Non-Luminal 153 (43 %) 206 (57 %) \0.001 \0.001 4.21 (2.10, 8.42)
Luminal 20 (8 %) 229 (92 %) Ref.
MammaPrint
Low Risk 5 (7 %) 63 (93 %) \0.001
High Risk 168 (31 %) 372 (69 %)
pCR pathologic complete response, NCT neoadjuvant chemotherapy, OR odds ratio, CI confidence interval, IHC immunohistochemistry, PR
progesterone receptor, ER estrogen receptor
a Included in multivariate modeling of dichotomized tumor size and molecular subtype
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HER2 subgroup, OR 0.44, 95 % CI 0.15, 1.24, p = 0.119;
Luminal subgroup, OR 1.9, 95 % CI 0.59, 6.17,
p = 0.286).
With the use of the pCR definition excluding nodal
status (ypT0/is), the pCR rates were slightly higher; how-
ever, there was no difference in statistically significant
versus nonsignificant analyses (data not shown).
DISCUSSION
The NBRST registry provides a unique opportunity to
study whether smaller tumors are likely to demonstrate
pCR. This would imply an associated improved survival. In
this current analysis of the NBRST study, we found that
although size was correlated inversely with the frequency
of pCR in BluePrint HER2 and Basal subtypes, this was not
demonstrated in the multivariate logistic regression anal-
yses, where BluePrint molecular subtype was the strongest
of the characteristics associated with pCR (grade, HER2,
PR, and lymph node status).
Patients who experience pCR defined as ypT0 ypN0 or
ypT0/is ypN0 have improved survival.1,3 In our prospec-
tive registry study, we used the recommended definition of
pCR (ypT0/isN0). All pCRs were verified with a deiden-
tified copy of the surgical pathology report. The overall
pCR rate to NCT of 28 % in our study is higher than the
pCR rate of 20 % using the same definition in recently
published meta-analyses.1,3 This may be because in our
study almost all clinical HER2-positive patients received
trastuzumab, while this was not yet the case in the pooled
meta-analyses. In the meta-analyses of Cortazar et al.,
patients with clinical T1 or T2 tumors had nonstatistically
significant higher pCR rates than patients with T3 and T4
tumors. Furthermore, clinical tumor size was not signifi-
cantly correlated with an increase in overall survival.3
Another study investigating clinical characteristics and
pCR association found an association of tumor size and
pCR in univariate analysis, which disappeared in multi-
variate analysis.9
Tumor size and lymph node status are the two most
important determinants in the AJCC staging manual.
Tumor size correlates with long-term survival, as patients
with smaller tumors have a lower T stage and generally a
better long-term prognosis from their breast cancer com-
pared to those with larger tumors and a higher T stage.10
Whitworth et al. have previously reported in the NBRST
study on the impact of MammaPrint/BluePrint molecular
subtypes and the frequency of pCR in contrast to clinical
subtypes (derived by ER, PR, and HER2). Luminal A and
B tumors do not usually respond with a pCR to NCT, while
pCR rates are significantly higher in HER2 and Basal
subtypes.6 Some ER-positive highly proliferative tumors
do respond to chemotherapy; indeed, identification of
patients who are best treated by endocrine therapy versus
cytotoxic chemotherapy is an area of great current interest
and active investigation in clinical trials.
It also has been shown that patients with HER2-positive
or triple-negative cancers are more likely to experience
improved long-term survival if they have a pCR after
NCT.1–5
Even though tumor size would intuitively be a clinical
determinant of pCR, the current unplanned subanalysis in
the prospective neoadjuvant NBRST study showed that the
adjusted OR for tumor size was not statistically significant
in any of the BluePrint molecular subgroups. Factors sig-
nificantly associated with pCR were PR status, HER2
status, grade, lymph node status, and BluePrint molecular
subtyping, which had the strongest correlation.
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